Impax Draws FTC Scrutiny for Tower Deal

Überblick


Raymond Jacobsen and Jon Dubrow were noted as counsel to Impax Laboratories in the FTC’s antitrust review of the company’s proposed acquisition of privately held drugmaker Tower Holdings Inc. The FTC has extended its review of the $700 million transaction.